Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stacy Smith-Foley

Diagnostic Radiology Little Rock, AR Medical Doctor

NPI 1285686576 CMS profile 427878

8901 Carti Way, Little Rock, AR 72205

Open in the dashboard

General payments

$106,012

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacy Smith-Foley of Little Rock, AR is reported in the CMS Open Payments database as having received $106,012 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,678 6
2024 General $13,187 23
2023 General $48,682 68
2022 General $12,702 23
2021 General $9,421 10
2020 General $14,800 13
2019 General $4,542 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Smith-Foley
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Stacy Smith-Foley were reported at $2,678. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Stacy Smith-Foley Diagnostic Radiology median Middle half National median
2019 $4,542 $108 $29–$318 $163
2020 $14,800 $65 $21–$252 $114
2021 $9,421 $92 $24–$292 $132
2022 $12,702 $104 $29–$294 $149
2023 $48,682 $110 $29–$337 $160
2024 $13,187 $113 $30–$356 $164
2025 $2,678 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Hologic Inc $67,213 83 payments
  2. Myriad Women's Health, Inc. $26,626 34 payments
  3. Myriad Genetic Laboratories, Inc. $7,817 13 payments
  4. Gen-Probe, Inc. $3,151 3 payments
  5. Hologic, LLC $602 9 payments
  6. Sirius Medical Systems $116 1 payment
  7. Siemens Medical Solutions USA, Inc. $111 1 payment
  8. SCYNEXIS, Inc. $92 1 payment
  9. Genentech USA, Inc. $84 1 payment
  10. Caris MPI, Inc. $78 1 payment
  11. Other $124 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $77,118 61 payments
  2. Honoraria $15,625 5 payments
  3. Travel and Lodging $9,622 33 payments
  4. Food and Beverage $3,603 51 payments
  5. Education $44 2 payments
Products named General payments · program years 2019–2025
  1. myRisk Oncology $31,742 44 payments
  2. AIXPLORER ULTIMATE $13,138 20 payments
  3. BREVERA BREAST BIOPSY SYSTEM $11,161 17 payments
  4. DIAGNOSTIC ULTRASOUND IMAGING SYSTEM $7,188 4 payments
  5. I -VIEW CONTRAST ENHANCED DIGITAL MAMMOGRAPHY $3,151 3 payments
  6. TULOC $3,150 1 payment
  7. myRisk Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis $2,700 3 payments
  8. Viera $2,061 1 payment
  9. Tumark $1,750 2 payments
  10. Localizer $792 7 payments
  11. Other $4,426 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$277,103

Of which drugs: $1,712

Medicare patients

1,268

Average age 73

Services billed

9,770

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 51%
Arthritis 48%
Depression 27%
Ischemic heart disease 24%
Diabetes 23%
Osteoporosis 22%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadopiclenol, 1 ml A9573 Office 36 358 $1,138
Injection, gadoterate meglumine, 0.1 ml A9575 Office 30 6,000 $574

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record